Download Free Immunological Diagnosis Of Leukemias And Lymphomas Book in PDF and EPUB Free Download. You can read online Immunological Diagnosis Of Leukemias And Lymphomas and write the review.

This two-and-a-half-day symposium has concentrated on main aspects of the rapidly expanding field ofleukocyte markers in hematology. While leukemias are already being 'phenotyped' routinely in clinical centers, continued research on the developmental sta ge of cells and cell membranes, expanding into a malignant clone, permits new snap shots on hemopoietic differentiation. Thus the discovery of leukemia-associated anti gens, which so far have not been found on subpopulations of normal cells, has greatly stimulated the discussion on 'differentiation antigens versus tumor antigens'. The proceedings reflect the considerable success which has been achieved very re cently in the classification of hemoblastomas. Consequently the number of leukemias which are unclassifiable by immunological methods have dwindled down to a small mi nority. New facts give rise to new questions. By including the main points of the discussions in the proceedings, we wanted to give the reader an opportunity to get an impression of the questions and conclusions raised and drawn by the participants on the basis of new - and frequently still unpublished - data. The editors thank both the contributors to this symposium, who made it a successful meeting and submitted their manuscripts punctually, and the publishers, who have provided a volume of high quality in good time. They are also grateful for the valuable cooperation from numerous colleages at the Institut fUr Hamatologie.
Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general on cology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.
An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.Following on the successful steps of the first edition, this Second Edition covers:various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients
New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future. * Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields
This book incorporates new information regarding normal immune cell development as well as diagnosis of acute leukemias, malignant lymphomas and characterization of stem cells for transplantation. It also discusses the clinical application of immunophenotyping in immunodeficiencies.
A practical and highly illustrated guide to the hematologic cancers, Understanding Leukemias, Lymphomas and Myelomas is an invaluable primer for everyone involved with these conditions, from specialists in training to interested patients. Using straightforward terminology and extensive color figures to describe and illustrate the current procedures
In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for leukemias and lymphomas. They apply reverse transcription PCR (RT-PCR) to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for Non-Hodgkin's Lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.
In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.